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Recent scientific breakthroughs in stem cell biology suggest that a sustainable treatment approach to cure diabetes
mellitus (DM) can be achieved in the near future. However, the transplantation complexities and the difficulty in
obtaining the stem cells from adult cells of pancreas, liver, bone morrow and other cells is a major concern. The
epoch-making strategy of transcription-factor based cellular reprogramming suggest that these barriers could be
overcome, and it is possible to reprogram any cells into functional β cells. Contemporary biological and analytical
techniques help us to predict the key transcription factors needed for β-cell regeneration. These β cell-specific
transcription factors could be modulated with diverse reprogramming protocols. Among cellular reprogramming
strategies, small molecule approach gets proclaimed to have better clinical prospects because it does not involve
genetic manipulation. Several small molecules targeting certain epigenetic enzymes and/or signaling pathways have
been successful in helping to induce pancreatic β-cell specification. Recently, a synthetic DNA-based small molecule
triggered targeted transcriptional activation of pancreas-related genes to suggest the possibility of achieving desired
cellular phenotype in a precise mode. Here, we give a brief overview of treating DM by regenerating pancreatic
β-cells from various cell sources. Through a comprehensive overview of the available transcription factors, small
molecules and reprogramming strategies available for pancreatic β-cell regeneration, this review compiles the
current progress made towards the generation of clinically relevant insulin-producing β-cells.
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Diabetes mellitus (DM) is an endocrine disorder associ-
ated with hyperglycemia and results in severe damage to
the blood vessels, eyes, kidneys and heart. According to
the latest survey, 347 million people worldwide suffer
from DM, and about 10% of adults in upper-middle- and
middle-income countries have the highest prevalence of
this disorder [1]. The DM pandemic could grow exponen-
tially in the next few decades and hence; there is a huge
economic burden on governments and individuals [2].
This chronic disease is categorized into three major types.
Type I DM (T1DM) is an autoimmune disease charac-
terized by insulin secretion deficiency instigated by the
destruction of insulin-producing β cells [3]. The non-* Correspondence: hs@kuchem.kyoto-u.ac.jp
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in any medium, provided the original work is pinsulin-dependent type 2 DM (T2DM) is a metabolic dis-
ease identified by insulin resistance and pancreatic β cell
dysfunction and is predominantly caused by a poor lifestyle
[4]. Recent studies indicate that mutations in certain genes
such as MADD (IG20) also play a critical role in causing
T2DM [5]. Gestational DM is another major form of DM
affecting about 3–10% of pregnancies, which in severe cases
can lead to neonatal and intrauterine fetal mortality [6].
Functional β cells could be derived from human pancre-
atic stem/progenitor cells through differentiation protocols.
However, resourcing issues and the lack for characterized
markers hamper the employment of these cells. Induced
pluripotent stem (iPS) cell technology extends the possibil-
ity of generating safe and functional pancreatic β cells
without the possible risk of implant rejection and offers a
potential cure for both T1DM and T2DM [7]. Recent pro-
gress in functional genomics provides us the sequence of 3
billion base pair human genome, and through loss-of-an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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scription factors (Figure 1A). Enforced transcriptional acti-
vation of some of these key genes can de-differentiate and/
or trans-differentiate the human somatic cells like fibro-
blasts into different cell types (Figure 1B) [8-10].
It is now possible to reprogram majority cell type pre-
cisely across lineage boundaries into desired cell type in-
cluding pancreatic β cells. Contemporary high-throughput
and characterization studies facilitate the screening and
identification of small molecules capable of modulating
several such key transcription factors [11]. A novel DNA-
based targeting epigenetic switch induced key transcription
factors associated with insulin secretion [12]. In this re-
view, we provide a critical overview of the strategies avail-
able for pancreatic β cell regeneration and list some of the
well-known and recently identified transcription factors.
We also give a detailed overview of the available repro-
gramming strategies including small-molecule control of
cell fate, discuss the major barriers hindering their clinical
use, and suggest future directions to achieve functional
pancreatic β cells efficiently and safely.
Review
Treatment options for DM
Since the discovery of insulin in 1921, insulin replacement
has become the main treatment for controlling plasmaFigure 1 Transcription factor-based cellular reprogramming. (A) Mode
generation sequencer (Shown in the arrow) facilitate us to gain insight into
diseases and/or cell fate modulation (B) Enforced transcriptional activation
cell types like pluripotent stem cells [8], cardiac progenitors [9] and hepatoglucose level [13]. Various treatment options are now avail-
able to manage both T1DM and T2DM, and they rely
largely on lifestyle changes such as dietary restrictions. The
major drugs to treat DM include insulin, glucagon-like pep-
tide 1 agonists, sulfonylureas, metformin, thiazolidine-
diones, α-glucosidase inhibitors, and dipeptidyl peptidase-4
inhibitors [14,15]. Despite remarkable progress and exciting
discoveries over the past decade, a permanent cure for DM
is yet to be achieved. The continuous need for antidiabetic
drugs in DM treatment and chronic hyperglycemia lead to
infections, ketoacidosis, hypoglycemia, and micro- and
macrovascular disorders affecting the retina and nervous,
renal, cardiovascular, and cerebrovascular systems [13]. It is
also difficult to maintain long-term glycemic control in pa-
tients with DM [16,17].
Through innovative integration of a continuous glu-
cose monitoring device and an insulin pump, a recent
FDA-approved device called a bio artificial pancreas from
Medtronic has been shown to improve the insulin treat-
ment in T1DM [18]. Bio artificial pancreas technology is
still at an early stage, and any long-term effects are yet to
be evaluated. Organ replacement therapies such as pancre-
atic transplantation are other strategies available to treat
DM; however, they have postoperative complications. Islet
allograft transplantation to replace β cells is another min-
imally invasive strategy. However, these cell transplantationrn experimental techniques like DNA chips, expression arrays and next
the human genome and identify novel genes/factors conferring to
of defined factors reprogram human somatic fibroblasts into different
cytes [10].
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limitations such as toxicity arising from the prolonged use
of immunosuppressants, graft cell loss and the damage
caused by autoimmune responses are some major concerns
[16,20]. The rapid advances in stem cell technologies sug-
gest the possibility to overcome the abovementioned limi-
tations of cell replacement therapy.
Stem cell therapy for DM
Stem cells are characterized by their remarkable ability
to self-renew and to acquire varying degrees of potency
for differentiation. Depending on the kind of division
(symmetric or asymmetric) modulated by the micro-
environment, stem cells give rise to either an offspring
preserving the characteristics of the parent stem cell or
another progeny with different potency and lineage po-
tential [13]. Throughout life, stem cells are maintained
as tissue-specific adult stem cells in the body. Some of
the primary stem cell sources available to achieve β cell
replacement include pancreatic stem cells, hepatic stem
cells and mesenchymal stem cells (MSCs). However,
lack of characterization studies hampers the classifica-
tion of any group of these cells as pancreatic stem cells.
A group of cells classed as pancreatic duodenal homeobox
1 (PDX1)+/ insulin (INS)+/glucose transporter 2 (SLC2A2)−
cells isolated from the pancreatic duct and pancreatic islet
tissues of transgenic mice have been classified as pancreatic
progenitor cells [20]. Recently, Lima et al. reprogrammed
the human exocrine pancreatic tissue into functional insu-
lin producing β-like cells by suppressing epithelial-to-
mesenchymal transition [21].
Considering the difficulty in obtaining pancreatic stem
cells, bone marrow stem cells such as MSCs are preferred
as they can be obtained easily [22]. The mechanism be-
hind the MSC-mediated stimulation of β cell regeneration
is still under debate [23]. Nevertheless, the evidence thus
far clearly substantiates MSCs as a clinical-friendly cell
source to treat DM owing to their immunomodulatory ef-
fects [24,25]. The shared developmental origin of hepatic,
pancreatic and common progenitor cells suggests hepatic
stem cells to be a better choice for achieving functional
insulin-producing β cells [26]. Accordingly, enforced tran-
scriptional activation of Pdx1 and Ngn3 by adenoviral
transfection maintained blood glucose levels by inducing
the differentiation of pancreatic endocrine and exocrine
cells [27]. Embryonic stem cells (ESCs) are pluripotent in
nature and might be stimulated to differentiate into pan-
creatic β cells through in vitro differentiation protocols.
Human ESC-derived pancreatic progenitor cells had the
capability to differentiate and mature, and they synthe-
sized insulin after being transplanted into mice [28]. Re-
cent reports on human ESC-derived insulin-producing
cells and demonstration of their capability to treat artifi-
cially induced hyperglycemia in mice substantiate theirtherapeutic prospects [29]. However, the sourcing of ESCs
and the ethical controversy regarding the destruction of
human embryos to produce them is a major concern. The
epoch-making discovery of iPS cell technology not only
eased the ethical controversy associated with human ESC
research but also opened up the possibility of reprogram-
ming any cell to a desired cellular phenotype [30]. Artifi-
cial induction of pluripotency in human somatic cells
through enforced transcriptional activation of four factors
(OCT4, SOX2, c-MYC, and KLF4) has opened up new
opportunities to reverse the fate of any terminally differ-
entiated cells into pluripotent stem cells [31]. Several
strategies are now available to achieve pluripotent stem cells
(Figure 2A) from a variety of cell sources (Figure 2B) [30].
Because the resulting iPS cells have all the potential of
ESCs [8], they can be readily differentiated into cells across
lineage boundaries. Derivation of β cells from iPS cells can
lead to clinically safe autologous cell populations and
hence can be an ideal source for transplantation therapy.
Using human iPS cells, Tateishi et al. first derived func-
tional insulin-producing β cells forming islet-like clusters
composed of C-peptide- and glucagon-positive cells [32].
In 2009, Maehr et al. demonstrated that iPS cells derived
from the skin fibroblasts of a patient with T1DM could
differentiate into insulin-producing/glucose-responsive
cells [33]. This innovative approach not only overcame the
barrier of immune rejection but also could aid in identify-
ing the genomic aberrations associated with T1DM. These
patient-derived iPS cells (termed DiPS) expressed and
stained positive for some of the pancreatic endocrine
markers including insulin, PDX1, NKX2-2, glucagon and
somatostatin. Interestingly, DiPS secreted insulin upon
glucose stimulation in a dose-dependent manner.
Zhang et al. improved the efficiency of differentiation
protocols and generated mature β-like cells expressing
markers (C-peptide, PDX1, GLUT2, MAFA, NKX6-1,
ISL-1 and NEUROD1) similar to adult β cells [34]. In
2010, Alipio et al. demonstrated the clinical potential of
iPS-cell-derived β cells by transplanting them into a
mouse model of T2DM. The transplanted cells corrected
the blood glucose levels and hyperglycemia for a long time
concomitantly with an increase in the in vivo concentra-
tion of insulin [35]. It is important to note here that the
iPS-derived insulin-producing cells engrafted stably and
became distributed to survive within the host tissue. This
approach was also successful in a mouse model of T1DM
and hence, suggested the clinical potential of iPS-derived
insulin-producing cells. Thus, it is now possible to gener-
ate human pancreatic endoderm and differentiate them
in vivo into glucose responsive mature islet cell types cap-
able of secreting C-peptide, insulin, glucagon, or somato-
statin. However, the current differentiation protocols
could not result in the generation of clinically significant
levels of human endocrine hormone. Recent reports focus
Figure 2 Approaches to iPS cell generation and the obstacles to their clinical translation. (A) In canonical approach (dark-gray arrow),
retroviral derived iPS cells could differentiate into varied cell types. However, the risk of tumor formation and their culture in xeno-medium can
inhibit the clinical translation of these cells. Alternative non-integrating approaches [30,31] in which the overexpression of defined reprograming
factors in various ways (green arrowhead) generate iPS cells that circumvent tumor formation, and when cultured in xeno-free medium, can avoid
the xeno contamination that hinders their clinical translation. Several bottlenecks, including epigenetic errors, low efficiency, and protocol
optimization, are highlighted (blue cylinder). (B) Various cell sources (microscopic images) can be reset for a journey back in time to iPS cells
(illustrated as the time machine icon) [30].
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that follow in vivo pancreatic developmental ontogeny
during differentiation of pluripotent stem cells [36,37].
Evaluation of long-term complications and identification
of key transcription factors could further support the
therapeutic potential of iPS cells in treating patients with
DM.
Cellular reprogramming and beta cell regeneration
Transcription factors and pancreatic development
There has been an exponential increase in studies report-
ing the identification of key genes/factors capable of
switching the cell fate from one state to another. Several
transcription factors operating at various stages of devel-
opment govern the sequential cascade of transcriptional
‘ON’ and ‘OFF’ mechanisms orchestrating pancreatic or-
ganogenesis. Through functional genomics and genetic
studies in mice, the functional role of some transcriptionfactors in coordinating normal organogenesis and the
subsequent specification into distinctive endocrine cell
types got identified [38]. Interestingly, single nucleotide
polymorphisms occur frequently in the binding sites of
these transcription factors [39]. Pancreatic and duodenal
homeobox 1 (PDX1) play a vital role as the master regula-
tor in different stages of pancreatic development and
islet cell morphogenesis [40]. PDX1 coordinates the in-
tricate transcriptional regulatory interactions between
the transcription factors, which confers to the multi-
potent pancreatic progenitors [38]. Considering its as-
sociation in regulating key β cell genes, PDX1 could be
a pharmacological target for β-cell defects in T2DM
[40]. Loss-of-function studies suggested the key role of
the self-regulating pancreas transcription factor 1 sub-
unit (PTF1A) in ensuring the lineage commitment of
pancreatic buds towards pancreatic progenitor fate [41].
The role of GATA factors in pancreas development got
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activation of both Gata4 and Gata6 perturbed the pro-
liferation of pancreatic progenitor cells and caused
faulty branching morphogenesis [42]. Likewise, simul-
taneous removal of Foxa1 and Foxa2 disturbed the early
event regulating the pancreas formation [43]. Interest-
ingly, in both the above-mentioned studies, loss of Pdx1
expression got associated with pancreatic hypoplasia
[42,43]. The sequential activation of the hepatocyte nuclear
factors (HNFs) like HNF1β and HNF6 expressing in endo-
derm and Pdx1 modulate the generation of pancreatic pro-
genitors [44]. Lynn et al. showed that the Sry/HMG box
transcription factor SOX9 could coordinate transcription
factors expressed in pancreatic progenitor cells [45].
The NK-homeodomain factor Nkx2.2 and its down-
stream gene Nkx6.1 plays a major role in the development
of insulin producing β-cells [46]. The LIM homeodomain
protein ISL1 is a critical factor for the development of the
dorsal exocrine pancreas and could direct mesenchymal
cells into either an endocrine or an exocrine state [47].
Itkin-Ansari et al. demonstrated that the basic helix-loop-
helix transcription factor NeuroD1 functions as both a
transcriptional activator and repressor in the establish-
ment and maintenance of mature endocrine cells [48].
Pax4 operate in concert with Pax6 to regulate normal pan-
creatic endocrine development and the master regulator
Pdx-1 controls the transcription of the insulin, GLUT-2,
GK, and Nkx6-1 in adult β-cells [49]. The transcription
factor neurogenin 3 (Ngn3) regulate the expression of Isl1,
Pax4, Pax6, and NeuroD1 and trigger the differentiation of
the β-cells from pancreatic endoderm to specify four
endocrine cell lineages of the pancreas [50]. Smith et al.
showed that the coordinating role of the regulatory factor
X, 6 (Rfx6) in the completion of the differentiation process
initiated by Ngn3. Since Rfx6 lies downstream of Ngn3
and upstream of other islet transcription factors, a com-
prehensive understanding of the role of Rfx6 could aid the
generation of β-cells from patients with DM [51]. The
essential role of the Maf factors like MafB and MafA in
the pancreatic β-cell differentiation and maturation is
known [52]. Gaining insights into the binding sites of
diverse transcription factors could aid the uncovering
of underexplored regulatory pathways affecting pan-
creatic β cells and causing DM.
Transcription factor-based cellular reprogramming
Cellular reprogramming strategies also suggest the pos-
sibility to achieve insulin-producing β cells by trans-
differentiating a wide range of cells. In particular, the cells
like hepatocytes and non-endocrine pancreatic cells sharing
the common lineage have a better chance to get repro-
grammed into β cells. Although these cells cannot secrete
insulin owing to the absence of some key factors, they ex-
press some common proteins. For example, hepatocytescannot make insulin from proinsulin but express the factors
responsible for stimulus-secretion coupling like glucose
transporter 2 and glucokinase, which also occur in the β
cell. Hence, fewer factors could be required to reprogram
such cells into insulin producing β cells. Accordingly,
adenovirus-mediated gene transfer of Pdx1 into mice re-
programmed hepatocytes into cells capable of decreasing
blood-glucose levels by producing insulin [53] and when
fused to VP16 transcriptional activation domain (Pdx1/
VP16), the efficiency of insulin producing cell generation
were significantly enhanced (Figure 3A) [54]. Subsequently,
the adenoviral transfection of PDX1 reprogrammed hepato-
cytes or the cells from human liver biopsies into cells cap-
able of controlling blood glucose levels in DM animals
(Figure 3A) [55]. Using the adeno-associated virus-
mediated transfer, Wang et al. later demonstrated that
the adenovirus transduction-triggered immune re-
sponse play a critical role in the reprogramming of he-
patocytes into β-like cells [56]. Likewise, viral-mediated
delivery of Ngn3, MafA, and Pdx1 reprogrammed the
acinar cells of the immunodeficient mice into insulin-
positive cells (Figure 3B) [57]. Despite the problems like
the inability to form organized and fully functional islet
structures, this proof-of-concept study suggested the
possibility to transform nonendocrine pancreatic cells
into cells having the β-like function.
Through the ectopic expression of Pax4, Collombat
et al. reprogrammed pancreatic progenitor cells express-
ing Pdx1 into glucagon expressing α cells, which then got
reprogrammed into insulin-positive cells (Figure 3B) [58].
However, in the older animals, the normoglycemia could
not be restored and the reason behind this effect is un-
clear. Nevertheless, this study suggested that to achieve
glucose-responsive, insulin-secreting β cells, alpha cells
from DM patients could serve as a potential cell source.
Kajiyama et al. showed that, upon Pdx1 transfection, the
adipose tissue-derived stem cells could differentiate into
IPCs in vivo and alleviate hyperglycemia in diabetic mice
(Figure 3C) [59]. Thus, the identification of optimal cell
sources and development of clinical-friendly reprogram-
ming approaches could lead to long-term stable treatment
strategy to cure DM.
Small molecules for pancreatic β cell regeneration
Recently, Deng et al. showed that it is possible to artifi-
cially induce pluripotency in mouse somatic cells using
seven small molecules alone [60]. This transgene free cel-
lular reprogramming strategy is expected to be clinically
relevant as small molecules are mostly non immunogenic
and their mode of employment is relatively easier than the
conventional reprogramming approaches [61]. Several
small molecules like the inhibitors of epigenetic enzymes
and signalling pathway factors aided the generation of
pluripotent stem cells from both mouse and human
Figure 3 Insulin producing cells (IPCs) from various cell sources. (A) Overexpression of the defined exogenous transcription factors (Pdx1;
Pdx1/VP16 (fusion protein) + NeuroD; Pdx1/VP16 (fusion protein) + Ngn3) in liver cells generate IPCs [53,54]. (B) IPCs could also be induced from
pancreatic non-β cells such as acinar cells and α-cells by forced expression of Ngn3 + Pdx1 + Mafa and Pax4, respectively [58]. (C) Adipose
tissue-derived stem cells could be differentiated into functional IPCs by transducing Pdx1 [59].
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vate or inhibit certain factors could also promote the dif-
ferentiation of pluripotent stem cells and even somatic
cells into functional β cells. Chen et al. identified through
high-content chemical screening that a small molecule
called (−)-indolactam V could trigger the differentiation of
human ESCs into Pdx1-expressing cells [62]. In a subse-
quent study, the TGF-β signalling pathway activating small
molecules induced endoderm formation from mouse ESCs
[63]. This inducer of definitive endoderm (IDE)-1 and its
derivative (IDE-2) further enabled the induction of pancre-
atic progenitors from mouse ESCs when treated along with
(−)-indolactam V [63]. The versatile differentiating agent
retinoic acid enhanced the generation of homogenous pan-
creatic PDX1 (+) pancreatic progenitor cells from human
ESCs and also promoted further differentiation into β cells
[64,65]. Dadheech et al. recently isolated a small molecule
called Swerstin from a perennial herb called Enicostemma
littorale and demonstrated its ability to differentiate
NIH3T3 cells into islet-like clusters [66]. Furthermore, theyshowed that normoglycemia could be restored upon the
transplantation of these cells in diabetic Balb/c mice. Using
high-throughput and cell-based screening studies, Shen
et al. identified and characterized a novel small molecule
‘WS6’ having the capability to promote β cell proliferation
in the primary islets of both rodent and human [67]. Ex-
pression of PDX1 plays an essential role in both β-cell re-
generation and maturation. In a very recent study, Yuan
et al. used a high-throughput qPCR study to screen 60,000
compounds and identified a small molecule capable of in-
ducing PDX1 expression in the human PANC-1 ductal car-
cinoma cell line [68]. This novel small molecule called
BRD7552 triggered transcriptionally permissive epigenetic
changes in the PDX1 promoter region and has shown the
capability to induce PDX1 expression in multiple cell lines
and primary human cells. Likewise, some known epige-
nome modifying small molecules have shown the capability
to promote β − cell differentiation by inducing key tran-
scription factors. For example, the DNA methyl trans-
ferase inhibitor 5-aza-2′-deoxycytidine (5-AZA) triggered
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turn promoted endocrine differentiation in the human
PANC-1 pancreatic ductal cell line [69] (Table 1).
Direct differentiation of hepatic stem-like WB cells into
insulin-producing cells got achieved using a combination
small molecules like selenite, 5-AZA, RA and Trichostatin
A (TSA), a regulator of chromatin remodeling and the fac-
tors like insulin and transferrin [70] (Figure 4). This study
suggests that it is possible to trans-differentiate optimal cell
source like hepatocytes into functional β cells. However,
lack of selectivity of some chromatin modifying enzymes
and requirement of multiple factors is a major concern.
Distinct DNA-based epigenetic switches for gene
regulatory networks
In recent times, small molecules with versatile properties
have shown the capability to induce multiple factors.
SAHA-PIP is one such multi-target small molecule having
sequence-specific DNA-binding hairpin pyrrole–imidazole
polyamides (PIPs) and SAHA, a pan-HDAC inhibitor. Syn-
thesized SAHA-PIPs targeting the promoter region of the
tumour suppressor gene p16 triggered sequence-specific
acetylation in HeLa cells (Figure 5A) [71]. Screening stud-
ies with a distinct set of SAHA-PIPs revealed certain
SAHA-PIPs capable of differentially inducing pluripotency
genes in mouse embryonic fibroblasts (MEFs) through ac-
tivation of epigenetic marks associated with transcription-
ally permissive chromatin [72,73].
Subsequent screening studies with a different set of
SAHA-PIPs revealed a potent SAHA-PIP called δ capable
of inducing multiple pluripotency genes and epithelial cell
markers [74]. Since δ-OMe, the non-functional SAHA-PIP
and SAHA alone did not activate any pluripotency genes;
it is reasonable to assume the role of SAHA and PIP as the
functional and DNA recognition module, respectively. A
larger number of the δ-induced genes belonged to the in-
tricate core pluripotency gene circuitry that includes 345
genes. Hence, PIP in δ could be directing SAHA to the
usually silent core pluripotency gene network for site-
specific epigenetic activation (Figure 5B).
Recently, a SAHA-PIP called K got categorized as the
first-ever small molecule capable of enforcing transcrip-
tional activation of meiosis-regulating germ cell genes in a
human somatic cell [75]. This result substantiates the re-
markable ability of SAHA-PIP to activate silent genes be-
cause these germ cell specific meiotic markers do not
normally occur in a somatic cell. GRPR (gastrin-releasing
peptide receptor) is a highly expressed factor in pancreas
and assists insulin secretion by stimulating the autonomic
nerves (Figure 5C) [76]. CD24 (cluster of differentiation 24)
is a cell adhesion molecule and a recent study revealed
CD24 as a marker for PDX1-positive pancreatic progenitors
derived from human ESCs [77]. CD24-positive cells were
shown to differentiate into insulin-producing cells. Recentscreening studies with an available set of 32 SAHA-PIPs re-
vealed that a SAHA-PIP called A (also labelled as 1) could
activate these two genes in human dermal fibroblasts.
Moreover, transcriptome analysis suggested that effect of A
is associated with pancreas-related function such as glucose
metabolism and diabetes [10] (Figure 5D). Chromatin im-
mune precipitation studies have revealed that SAHA-PIP
can induce site-specific chromatin modification to activate
the typically ‘silent genes’ in human somatic cells [75]. Be-
cause of the tunable potential, SAHA-PIP could be devel-
oped as a novel tool to achieve precisely reprogrammed
pluripotent stem cell and/or insulin producing β cell. Pre-
cisely reprogrammed cells with fewer factors should have
better clinical prospects and also could facilitate the
achievement of homogenous insulin producing cells, which
is a major bottleneck that hampers the clinical translation
of artificially reprogrammed cells.
Conclusion and Outlook
In general, diseases are characterized by dysregulation in
the transcriptional machinery, which is responsible for
the maintenance of the cellular homeostasis [78]. Re-
cently, clinicians have turned their attention to genetic
knowledge based therapeutic strategies to treat incurable
diseases like DM [30]. Current gene expression profiling
techniques helps us in predicting the transcription fac-
tors conferring to β cell regeneration [13]. In recent
years, an increasing number of genes get classified as the
potential therapeutic targets and/or cell-fate determining
transcription factors [5,10]. With the rise of cellular repro-
gramming strategy, it is now possible to modulate these
transcription factors and achieve desired cellular pheno-
type from a variety of cell sources. The reprogrammed in-
sulin producing cells should be functionally matured for
achieving clinically relevant numbers of endocrine cells.
Moreover, these cells should also survive long and be
engrafted properly inside the host cell environment. To
achieve such complex feat, strategies to achieve identical
islet-like structures having optimal access to nutrient and
oxygen after engraftment in vivo is required.
Optimal cell sources and the reprogramming strategies
also complicate the existing difficulties. For example, some
of the currently available reprogramming protocols harbor
the risk of transgene integration and mutagenesis, which
are not clinical friendly [29]. Consequently, transgene free
approaches to reprogram cells like employment of RNA,
proteins and/or small molecules have been gaining atten-
tion. In particular, reprogramming cells with small mole-
cules alone is accepted to have better clinical prospects
than the other reprogramming strategies.
Small molecules are also the most preferred drugs
among the clinicians and each year they out number the
other biological drugs [79]. High-throughput studies re-
vealed several small molecule inhibitors and/or activators
Table 1 Small molecules and pancreatic β-cell regeneration
Chemical Target Source Reference Notes




(IDE 1 (above) and IDE 2 (below)
Endoderm Mouse ESCs [63] TGF-β activator. Enables induction
of pancreatic progenitors from
mESCs with Indolactam V
Retinoic acid (RA) Pancreatic cells, β-cells Definitive endoderm [64,65]
Swertisin Islet-like cell clusters Mouse NIH3T3 cells [66]
WS6 - β-cells [67] IκB kinase pathway activator
(Promotes proliferation of β cells)
BRD7552 - Human islets and ductal cells [68] PDX1 expression.
5-aza-2’-deoxycytidine (5-AZA) Pancreatic endocrine cells PANC-1 human ductal cell line [69] DNA methylation inhibitor.
Abbreviations, PKC protein kinase C, ESCs embryonic stem cells, TGF-β transforming growth factor β.
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Figure 4 Small molecules and β cell induction. Liver epithelial stem-like white blood (WB) cells can be reprogrammed into insulin-producing
cells (IPCs) by sequential protocol using small molecules [68]. In the first stage, WB cells are dedifferentiated with 5-aza-2’-deoxycytidine (5-AZA)
and Trichostatin A (TSA). Then, retinoic acid (RA) and a mix of insulin, transferrin and selenite (ITS) are added to induce PDX1-positive pancreatic
precursor cells. Nicotinamide promotes maturation of IPCs in the last stage.
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generation of β cells. However, lack of sequence-specificity
and the requirement of multiple small molecules necessi-
tate the development of small molecules capable of mim-
icking the efficacy of their natural counterparts. To achieveFigure 5 SAHA-PIP: potential tool for selective transcriptional activati
(SAHA-PIP) conjugate capable of site-specific acetylation in the promoter re
core pluripotency gene network in mouse embryonic fibroblasts through s
(C) SAHA-PIP K and (D) SAHA-PIP A activates gene regulatory network asso
metabolism, respectively [12,75].the coordinated orchestration of gene expression observed
in nature, small molecules should act at both genetic and
epigenetic level to regulate the extremely complex gene
regulatory networks. A promising way to achieve targeted
transcriptional activation is to develop epigenetically activeon. (A) Chemical structure of SAHA-pyrrole-imidazole polyamide
gion of p16 tumor suppressor gene [71]. (B) SAHA-PIP `δ` triggers the
ite-specific epigenetic activation. In human dermal fibroblasts [74],
ciated with and germ cell and pancreas function such as glucose
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specific DNA sequences. One such class of multi-target
small molecules having the potential to achieve precise cel-
lular reprogramming is the customizable synthetic SAHA-
PIPs capable of modulating distinct biological networks
(Figure 5). Synthetic PIPs gain advantages over other nat-
ural DNA-binding proteins as effective transcriptional acti-
vators because they possess flexible covalent sites and can
bind to the methylated DNA sequences and disrupt the
packed chromatin structure [80-82]. Modification in the
structure of SAHA altered the specificity of `δ ` towards a
specific HDAC enzyme [83]. Thus, it is possible to at-
tach other epigenetic enzyme inhibitors to trigger vari-
able effects. Ligands that recognize 15–16 base pairs
can recognize a single site within the 3 billion base pair
human genome [84]. Major regions of the iPS epige-
nome retain the epigenetic memory of their tissue of
origin [85]. Chromatin-modifying enzymes act as both
facilitators of and barriers to the epigenetic remodeling of
differentiated cells into pluripotent stem cells [86]. Hence,
selective chromatin modifiers could modulate the compli-
cated transcriptional network, with less exogenous tran-
scription factors, thus efficiently reprogramming somatic
cells. In this context, small molecules, such as SAHA-
PIPs, that can induce sequence-specific chromatin modifi-
cations may be developed to erase the epigenetic memory
and aid the generation of clinical-grade reprogrammed
cells [87,88]. Cellular reprogramming using small mole-
cules alone also has certain limitations. For instance, a
certain bioactive small molecule can have variable efficacy
against different cell types. Cellular reprogramming with
small molecules alone can also trigger genetic instability
and the genetic integrity of the reprogrammed cells might
get affected [61]. The remarkable ability of pluripotent stem
cells to proliferate could also be an issue because the residual
undifferentiated cells may cause tumor formation. Therefore,
the clinical potential of the reprogrammed cells could be
increased with the development of small molecules capable
of selectively eliminating human pluripotent cells like
PluriSIn#1 [89] and/or programmable SAHA-PIPs.
Identification of novel transcription factors and develop-
ment of strategies for their modulation could lead to effective
regeneration of pancreatic β-cells. Importantly, even after
transplantation these precisely reprogrammed cells should
still retain the capability to produce insulin. The safety re-
quirements associated with any transplantation studies like
dosage, genetic stability, possible pathogenicity and toxicity
towards host tissue needs to be considered. Nevertheless,
recent developments in diabetes research and increasing
interest on the intellectual integration of diverse tech-
niques suggest that a permanent cure is not too far.Competing interests
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